$ABT · Abbott Laboratories
Abbott Laboratories filed a Form 4 with the SEC on October 2, 2026, reporting a transaction by John G. Stratton, a director of the company. On September 30, 2026, Stratton acquired 397 stock equivalent units at a price of $98.83 per unit. These units were credited to a stock equivalent unit account under a grantor trust established by the director, representing director fees that track the return of Abbott common shares and are generally paid in cash at age 65 or upon retirement from the board.
Following the reported transaction, Stratton beneficially owned 14,499 stock equivalent units directly. The filing also notes that this balance includes stock equivalent units acquired through a dividend reinvestment feature. The Form 4 is a routine statement of changes in beneficial ownership required under Section 16(a) of the Securities Exchange Act of 1934.